Ann: Transcript of CAN-003 data conference call , page-16

re: Ann: Transcript of CAN-003 data conferenc... Hi macenroc

1 point to keep in mind about the Edison piece, it was released prior to the announcement of Fast Track status being granted by the FDA. Depending on how much you think that will impact the timeline, the market launch potentially moves up. It also doesn't consider the possibility of Breakthrough Therapy Designation, which would be the real game changer.

P/E for Biotech's.....that's a head scratcher!
At one point DNDN was priced at an absurd 40 times earnings, then came plummeting down when revenue failed to meet expectations, production costs blew out and the massive debt load became apparent.

Personally, I like to work on the basis of a conservative P/E of 10-13 x stabilised earnings, post commercial launch.